These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35502888)

  • 1. Knowledge gaps in the management of refractory reflux-like symptoms: Healthcare provider survey.
    Armstrong D; Hungin AP; Kahrilas PJ; Sifrim D; Sinclair P; Vaezi MF; Sharma P
    Neurogastroenterol Motil; 2022 Oct; 34(10):e14387. PubMed ID: 35502888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.
    Galindo G; Vassalle J; Marcus SN; Triadafilopoulos G
    Dis Esophagus; 2013 Jul; 26(5):443-50. PubMed ID: 22862422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical characteristics and esophageal function tests of refractory gastroesophageal reflux disease].
    Wang K; Tao HQ; Wang Q; Xu ZJ; Xia ZW; Ge Y; Duan LP
    Zhonghua Nei Ke Za Zhi; 2020 Nov; 59(11):880-886. PubMed ID: 33120492
    [No Abstract]   [Full Text] [Related]  

  • 4. Tailored therapy guided by multichannel intraluminal impedance pH monitoring for refractory non-erosive reflux disease.
    Ranaldo N; Losurdo G; Iannone A; Principi M; Barone M; De Carne M; Ierardi E; Di Leo A
    Cell Death Dis; 2017 Sep; 8(9):e3040. PubMed ID: 28880273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation and Treatment of Patients with Persistent Reflux Symptoms Despite Proton Pump Inhibitor Treatment.
    Spechler SJ
    Gastroenterol Clin North Am; 2020 Sep; 49(3):437-450. PubMed ID: 32718563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Symptom association probability does not reliably distinguish functional heartburn from reflux hypersensitivity.
    Choksi Y; Slaughter JC; Sharda R; Higginbotham T; Lal P; Vaezi MF
    Aliment Pharmacol Ther; 2018 Apr; 47(7):958-965. PubMed ID: 29372566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Algorithmic approach to patients presenting with heartburn and epigastric pain refractory to empiric proton pump inhibitor therapy.
    Roorda AK; Marcus SN; Triadafilopoulos G
    Dig Dis Sci; 2011 Oct; 56(10):2871-8. PubMed ID: 21512760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alginate antacid (Gaviscon DA) chewable tablets reduce esophageal acid exposure in Chinese patients with gastroesophageal reflux disease and heartburn symptoms.
    Yuan YZ; Fang JY; Zou DW; Levinson N; Jenner B; Wilkinson J
    J Dig Dis; 2016 Nov; 17(11):725-734. PubMed ID: 27622897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Model to Select On-Therapy vs Off-Therapy Tests for Patients With Refractory Esophageal or Extraesophageal Symptoms.
    Patel DA; Sharda R; Choksi YA; Slaughter JC; Higginbotham T; Garrett CG; Francis DO; Ravi K; Hasak S; Katzka D; Gyawali CP; Vaezi MF
    Gastroenterology; 2018 Dec; 155(6):1729-1740.e1. PubMed ID: 30170117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastroesophageal reflux disease-related symptom recurrence in patients discontinuing proton pump inhibitors for Bravo
    Schey R; Alla SP; Midani D; Parkman HP
    Rev Gastroenterol Mex; 2017; 82(4):277-286. PubMed ID: 28385467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Most Patients With Gastroesophageal Reflux Disease Who Failed Proton Pump Inhibitor Therapy Also Have Functional Esophageal Disorders.
    Abdallah J; George N; Yamasaki T; Ganocy S; Fass R
    Clin Gastroenterol Hepatol; 2019 May; 17(6):1073-1080.e1. PubMed ID: 29913281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of antacids, alginates and proton pump inhibitors: a survey of the general Danish population using an internet panel.
    Lødrup A; Reimer C; Bytzer P
    Scand J Gastroenterol; 2014 Sep; 49(9):1044-50. PubMed ID: 24874283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How many cases of laryngopharyngeal reflux suspected by laryngoscopy are gastroesophageal reflux disease-related?
    de Bortoli N; Nacci A; Savarino E; Martinucci I; Bellini M; Fattori B; Ceccarelli L; Costa F; Mumolo MG; Ricchiuti A; Savarino V; Berrettini S; Marchi S
    World J Gastroenterol; 2012 Aug; 18(32):4363-70. PubMed ID: 22969200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adding Acotiamide to Gastric Acid Inhibitors Is Effective for Treating Refractory Symptoms in Patients with Non-erosive Reflux Disease.
    Yamashita H; Okada A; Naora K; Hongoh M; Kinoshita Y
    Dig Dis Sci; 2019 Mar; 64(3):823-831. PubMed ID: 30465175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of early wireless esophageal pH monitoring in diagnosing functional heartburn in refractory gastroesophageal reflux disease.
    Park EY; Choi MG; Baeg M; Lim CH; Kim J; Cho Y; Park J; Lee I; Kim S; Choi K
    Dig Dis Sci; 2013 Oct; 58(10):2933-9. PubMed ID: 23765257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and clinical characteristics of refractoriness to optimal proton pump inhibitor therapy in non-erosive reflux disease.
    Ribolsi M; Cicala M; Zentilin P; Neri M; Mauro A; Efthymakis K; Petitti T; Savarino V; Penagini R
    Aliment Pharmacol Ther; 2018 Nov; 48(10):1074-1081. PubMed ID: 30294924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?
    de Bortoli N; Martinucci I; Savarino E; Bellini M; Bredenoord AJ; Franchi R; Bertani L; Furnari M; Savarino V; Blandizzi C; Marchi S
    Neurogastroenterol Motil; 2014 Jan; 26(1):28-35. PubMed ID: 23992024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of improvement of impaired chemical clearance characterizes PPI-refractory reflux-related heartburn.
    Frazzoni M; Frazzoni L; Tolone S; De Bortoli N; Savarino V; Savarino E
    Am J Gastroenterol; 2018 May; 113(5):670-676. PubMed ID: 29681623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased proximal reflux in a hypersensitive esophagus might explain symptoms resistant to proton pump inhibitors in patients with gastroesophageal reflux disease.
    Rohof WO; Bennink RJ; de Jonge H; Boeckxstaens GE
    Clin Gastroenterol Hepatol; 2014 Oct; 12(10):1647-55. PubMed ID: 24184737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ARE THE PERSISTENT SYMPTOMS TO PROTON PUMP INHIBITOR THERAPY DUE TO REFRACTORY GASTROESOPHAGEAL REFLUX DISEASE OR TO OTHER DISORDERS?
    Azzam RS
    Arq Gastroenterol; 2018 Nov; 55Suppl 1(Suppl 1):85-91. PubMed ID: 30304291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.